NEW YORK, December 28, 2025, 23:04 ET — Market closed
- A SPAC III Acquisition Corp shares last traded at $24.01 after a roughly 79% jump in the last session.
- The stock swung between $13.45 and $55.37 and saw multiple volatility-related trading pauses on Nasdaq.
- Heavy share redemptions this fall left a much smaller pool of shares available to trade, company filings showed.
A SPAC III Acquisition Corp shares surged in the last U.S. session and then whipped around in thin year-end trading, a setup that can magnify moves in small “blank-check” stocks.
The Nasdaq-listed stock last traded at $24.01, up 10.45 from its prior close, according to LSEG data.
Nasdaq halted trading in the stock for volatility at least twice during Friday’s session, Refinitiv messages showed.
The moves matter now because the company’s publicly tradable share count has shrunk sharply after redemptions, increasing the odds that aggressive buying or selling can push prices quickly in either direction.
In a quarterly filing, the company said 5,717,419 Class A shares were redeemed at its 2025 extraordinary general meeting, leaving about $2.9 million in its trust account; it also said the sponsor held about 76.4% of the company’s 2,337,581 outstanding ordinary shares after the redemption.
A SPAC III is a special purpose acquisition company, or SPAC — a shell company that raises cash in an IPO and looks for a private business to merge with.
On Friday, the stock traded between $13.45 and $55.37, and volume hit about 7.4 million shares, LSEG data showed.
Benzinga reported the shares were up about 82% to $24.38 in morning trading before the stock later settled back near $24.
The company has said it signed a merger agreement with Bioserica International Limited, a British Virgin Islands company it described as a developer and manufacturer of bio-based antimicrobial materials.
Under the terms described in filings, the deal consideration was structured as stock and pegged to a $10.00 per-share reference price, with aggregate consideration described at $200 million plus additional shares tied to conditions.
In October, shareholders approved an extension that gave the SPAC until November 12, 2026 to complete an initial business combination, a filing showed — a move that can keep a SPAC alive but also concentrates trading in a smaller post-redemption float.
The broader tape offered little help for price discovery. “We’re just simply catching our breath today after the holiday,” said Ryan Detrick, chief market strategist at Carson Group, in a Reuters market wrap on the post-Christmas session. Reuters
A SPAC III was also among the Nasdaq Composite’s top gainers in that session alongside other small-cap movers such as Picocela and Davis Commodities, according to an Investing.com market report.
Before the next session, traders will watch Monday’s U.S. pending home sales report for November due at 10:00 a.m. ET — a data point that can sway rate expectations and risk appetite during year-end trading.
Investors also have the Federal Reserve’s December meeting minutes on Tuesday, along with other late-month U.S. economic releases, as markets move through the final trading days of the year, Barron’s reported.
For ASPC specifically, the next catalyst is likely to be an SEC filing around the proposed Bioserica transaction — including any proxy/prospectus paperwork or changes to deal terms — and any updated disclosure on cash remaining in trust after redemptions.
Technically, Friday’s wide range between roughly $13 and $55 set clear reference levels for the next session; further sharp moves could trigger more volatility pauses under exchange rules.
Sources (links): SEC filings ; Refinitiv halt headlines ; market data ; macro calendar
